leisure time -WSS

leisure time

author：focus 2025-09-03 14:39:13 - browse：55

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： A Q&A with the global head of Boehringer Ingelheim's innovation unit

WSS

Dramatically reducing cancer deaths requires the PASTEUR Act

Dramatically reducing cancer deaths requires the PASTEUR Act

Stem cell clinics for heart failure: buyer be wary

For BCIs, commercial hurdles may be bigger than scientific ones

ER docs worry over extreme heat as a 'mass casualty event'

Bristol 'take

explore

leisure time

explore

Medicare details structure of new drug price negotiation program

Colorectal cancer study finds potential in overlooked immune cell

Hepatitis C has a cure — but many Americans still lack access to it

The future of health care in the House

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Analysis of telehealth claims data suggest service duplication

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

2 US Navy sailors arrested for allegedly spying for China

Medicare proposal to cover medical devices draws a mixed reaction

Nearly two

focus

FDA authorizes Novavax’s updated Covid

What Mike Pence has said that could be used in a Donald Trump trial

What Henrietta Lacks settlement says about racism in medicine

My superpower is killing ticks

Gilgo Beach: Police identify another victim in serial killing investigation

The drug industry sees a key ally in the Senate prevail

focus

Wikipedia

hotspot

Wikipedia